To improve the DMPK characteristics, many studies have explored the coupling of PROTAC payloads with monoclonal antibodies to create a new molecule known as “Antibody-Drug Conjugates (DAC).” This allows for more effective delivery of PROTAC degraders in vivo. ▲ Structure of DAC (Image Source: Reference 1) Compared to PROTAC molecules, DAC has several potential advantages: … Read more
The Emergence and Advantages of DAC Cancer therapeutics need to achieve a balance between efficacy and safety, even targeted chemotherapy does not always only kill abnormal cancer cells, non-specific toxicity can lead to a low therapeutic index and side effects. The technology of proteolysis-targeting chimeras (PROTACs), which achieves therapeutic effects by promoting the degradation of … Read more
Introduction Degrader-Antibody Conjugates (DAC) are a novel entity that combines the payload of Protein Degradation Targeting Chimeras (PROTAC) with monoclonal antibodies through a type of chemical linker (DAC =PROTAC + ADC). This article collects several examples of DAC from scientific and patent literature and documents specific challenges associated with DAC construction. Overall, these examples indicate … Read more